Universitat Autònoma de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (33)

2023

  1. Alcohol-related liver disease phenotype impacts survival after an acute variceal bleeding episode

    Liver International, Vol. 43, Núm. 7, pp. 1548-1557

  2. Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding

    Gut, Vol. 72, Núm. 4, pp. 749-758

  3. Liver Transplantation for Porto-sinusoidal Vascular Liver Disorder: Long-term Outcome

    Transplantation, Vol. 107, Núm. 6, pp. 1330-1340

  4. Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis

    Hepatology (Baltimore, Md.), Vol. 77, Núm. 6, pp. 2052-2062

2022

  1. Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease

    Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 10, pp. 2276-2286.e6

  2. Non-invasive tests for clinically significant portal hypertension after HCV cure

    Journal of Hepatology, Vol. 77, Núm. 6, pp. 1573-1585

  3. Preventing (First) Decompensation: Consensus Statements of Panel 5

    Portal Hypertension VII: Proceedings of the 7th Baveno Consensus Workshop: Personalized Care in Portal Hypertension (Springer International Publishing), pp. 443-446

2021

  1. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis

    Journal of Hepatology, Vol. 75, Núm. 3, pp. 589-599

  2. Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 342-350

  3. Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data

    Gastroenterology, Vol. 160, Núm. 1, pp. 193-205.e10

  4. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis

    Journal of Hepatology, Vol. 74, Núm. 5, pp. 1097-1108

  5. Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

    JHEP Reports, Vol. 3, Núm. 6

2020

  1. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF

    Journal of Hepatology, Vol. 72, Núm. 4, pp. 688-701

  2. Correction to ‘Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF’ [J Hepatol 2020 (72) 688–701] (Journal of Hepatology (2020) 72(4) (688–701), (S0168827819306968), (10.1016/j.jhep.2019.11.009))

    Journal of Hepatology

  3. Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 2, pp. 313-327.e6

  4. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

    Journal of Hepatology, Vol. 73, Núm. 5, pp. 1082-1091

  5. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology

    Journal of Hepatology, Vol. 73, Núm. 4, pp. 842-854

2019

  1. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

    The Lancet, Vol. 393, Núm. 10181, pp. 1597-1608

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2017

  1. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study

    Transplant International, Vol. 30, Núm. 10, pp. 1041-1050